US · Healthcare · Biotechnology
EPS came in at -1.81 against a street estimate of -1.30 — a miss of 39.2%.
Analysts rate Corbus Pharmaceuticals Holding a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $34.89.
| Fund | Stake |
|---|---|
| Cormorant Asset Management, LLC | 12.12% |
| Orbimed Advisors LLC | 8.98% |
| BlackRock Inc | 6.88% |
| Aberdeen Group PLC | 6.83% |
| Vanguard Capital Management, LLC | 3.93% |
| Jones Hill Capital LP | 3.38% |
| Prosight Management, LP | 3.36% |
| Stonepine Capital Management Llc | 2.20% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Corbus Pharmaceuticals Holding — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.